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Research
AbstrACt
Objectives The objectives of the study were to assess 
glycaemic control in patients with type 2 diabetes (T2DM) 
at a tertiary care diabetes centre in Ningbo, China and 
to determine factors that independently predict their 
glycaemic control.
Design Retrospective cross-sectional study using an 
existing database, the Diabetes Information Management 
System.
setting Tertiary care diabetes centre in Ningbo, China.
Participants The study included adult patients with 
T2DM, registered and received treatment at the diabetes 
centre for at least six consecutive months. The study 
inclusion criteria were satisfied by 1387 patients, from 1 
July 2012 to 30 June 2017.
Primary outcome measure Glycaemic control (poor was 
defined as glycated haemoglobin (HbA1c)>=7% or fasting 
blood glucose (FBG)>7.0 mmol/L).
results In terms of HbA1c and FBG, the 5-year period 
prevalence of poor glycaemic control was 50.3% and 
57.3%, respectively. In terms of HbA1c and FBG, the odds 
of poor glycaemic control increased with the duration of 
T2DM (>1 to 2 years: OR 1.84, 95% CI 1.06 to 3.19; >2 to 
4 years: 3.32, 1.88 to 5.85 and >4 years: 5.98, 4.09 to 
8.75 and >1 to 2 years: 2.10, 1.22 to 3.62; >2 to 4 years: 
2.48, 1.42 to 4.34 and >4 years: 3.34, 2.32 to 4.80) and 
were higher in patients residing in rural areas (1.68, 1.24 
to 2.28 and 1.42, 1.06 to 1.91), with hyperlipidaemia 
(1.57, 1.12 to 2.19 and 1.68, 1.21 to 2.33), on diet, 
physical activity and oral hypoglycaemic drug (OHD) as 
part of their T2DM therapeutic regimen (1.80, 1.01 to 3.23 
and 2.40, 1.36 to 4.26) and on diet, physical activity, OHD 
and insulin (2.47, 1.38 to 4.41 and 2.78, 1.58 to 4.92), 
respectively.
Conclusions More than half of patients with T2DM 
at the diabetes centre in Ningbo, China have poor 
glycaemic control, and the predictors of glycaemic control 
were identified. The study findings could be taken into 
consideration in future interventional studies aimed at 
improving glycaemic control in these patients.
IntrODuCtIOn
China has the world’s largest type 2 diabetes 
(T2DM) epidemic, a complex metabolic 
disorder which has major health, social and 
economic consequences. Almost 11% of all 
adults are currently living with T2DM (around 
114 million). This number is expected to 
increase to around 150 million by 2040.1 Its 
chronic hyperglycaemia is associated with 
long-term complications (eg, cardiovascular 
disease) and even death.2 In China, T2DM 
and its complications contribute to almost 
1 million deaths each year. Alarmingly, 
nearly 40% of these deaths are premature 
(ie, in people below the age of 70).3 China 
spends upwards of US$ 25 billion a year on 
the management of T2DM and 13% of its 
medical expenditures are directly caused by 
T2DM.4 In spite of this, many patients with 
T2DM have poor glycaemic control (51%–
68%).5–9 Unfortunately, these figures are 
much higher as compared with many devel-
oped countries.10 11 
strengths and limitations of this study
 ► This is the first study to explore glycaemic control 
in patients with type 2 diabetes at the tertiary care 
diabetes centre in Ningbo, China and as far as we 
are aware, in the Zhejiang province of China.
 ► Glycated haemoglobin (which reflects the average 
blood glucose level over the past 3 months) and fast-
ing blood glucose (a short-term index) were used to 
determine glycaemic control, which in turn provided 
a complete picture.
 ► Missing data could lead to bias but were generally 
low in this study. Multiple regression analyses in-
cluded a sample with missing values for the adjust-
ed variables.
 ► This retrospective study was conducted using an ex-
isting database, which is primarily developed for the 
clinical purpose and not for research (ie, issues with 
routinely collected data were present).
 ► As this was a cross-sectional study, it was not pos-
sible to determine the causal association between 
different variables and glycaemic control.
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In China, hospitals are categorised into three: primary 
care, secondary care and tertiary care. A primary care 
hospital (community hospital with general practitioners) 
usually has less than 100 beds and are mainly respon-
sible for providing preventive care and minimal health 
services. A secondary care hospital usually has 100 to 500 
beds and are mainly responsible for providing health 
services and for performing a role in medical education 
and research. A tertiary care hospital usually has more 
than 500 beds and are mainly responsible for providing 
specialist health services and for performing a bigger role 
in medical education and research.12 In China, people 
(including patients with T2DM) can attend any hospital 
of their choice. In other words, it is not based on any 
referral system by the community hospital with general 
practitioners.
Ningbo is one of the most economically developed 
Chinese cities, located in the northeast Zhejiang prov-
ince. In 2015, the prevalence of T2DM in people over 
40 years of age in the city was around 21%.13 There are 
152 community hospitals with general practitioners, 21 
secondary hospitals and 21 tertiary care hospitals in the 
city. Ningbo First Hospital, with 1600 beds, is a tertiary care 
hospital. Local patients, as well as those from surrounding 
areas, visit this hospital.14 The hospital’s diabetes centre 
has a team of qualified and experienced diabetes experts. 
Until now, no research has been conducted to explore 
glycaemic control in patients with T2DM at the diabetes 
centre. The objectives of the study were to assess their 
glycaemic control and to determine factors that inde-
pendently predict their glycaemic control. Knowledge 
of factors associated with the poor glycaemic control in 
these patients would provide valuable information about 
strategies that healthcare professionals and providers can 
address to improve their glycaemic control.
MethODs
study design, data source and period
A retrospective cross-sectional study was conducted using 
an existing computerised medical records’ database, the 
Diabetes Information Management System. This database 
was developed by the Yinal Software Corporation, China 
for the diabetes centre. The study period was from 1 July 
2012 to 30 June 2017 (5 years) and the database included 
6699 patients.
study population, inclusion and exclusion criteria
The study included adult (18 years of age or older) 
patients, diagnosed with T2DM and registered and 
received treatment at the diabetes centre for at least six 
consecutive months. In China, patients with T2DM are 
usually given at least 6 months’ time to adjust to their 
T2DM therapeutic regimen and control their blood 
glucose levels. Those diagnosed with type 1 diabetes, 
gestational diabetes, secondary diabetes, unknown type 
of diabetes or endocrine diseases (such as Cushing 
syndrome and hyperthyroidism which may increase their 
blood glucose levels) were excluded from the study. The 
study inclusion criteria were satisfied by 1387 patients.
study variables
The following variables (measured after 6 months of 
treatment at the diabetes centre) were extracted from 
the database: age: 18–39 years, 40–59 years or ≥60 years; 
sex; education: university/college, class 7 to 12, class 1 to 
6 or no qualifications; occupation: manual workers (ie, 
more physical than mental work), non-manual workers 
(ie, more mental than physical work) or never worked/
retired; marital status: married or single/divorced/
widowed; residence: urban or rural based on the ‘hukou’ 
system (ie, residence registration system in China)15; 
health insurance; smoking (current status); alcohol 
drinking (current status); family history of T2DM (any 
parent or sibling); duration of T2DM: ≤1 year, >1 to 2 
years, >2 to 4 years or >4 years; number of visits to the 
diabetes centre for T2DM since registration; T2DM ther-
apeutic regimen: only diet and physical activity, diet and 
physical activity and oral hypoglycaemic drug ((OHD) 
metformin, acarbose, sulfonylureas, meglitinides and/or 
thiazo-lidinediones), diet and physical activity and insulin 
(long-term insulin, intermediate insulin, rapid-acting 
insulin and/or premix insulin) or diet and physical 
activity, OHD and insulin16; body mass index (BMI): under 
(<18.5 kg/m2), normal (18.5–23.9 kg/m2), overweight 
(24.0–27.9 kg/m2) or obese (≥28 kg/m2)17; hypertension 
(diagnosis based on blood pressure ≥140/90 mm Hg); 
hyperlipidaemia (diagnosis based on serum lipids—total 
cholesterol ≥4.5 mmol/L or triglycerides ≥1.7 mmol/L) 
and blood glucose levels. Following the current guide-
line for the prevention and management of T2DM in 
China, poor glycaemic control was defined as glycated 
haemoglobin (HbA1c)≥7% or fasting blood glucose 
(FBG)>7.0 mmol/L.16 The HbA1c was estimated using 
the high-performance liquid chromatographic method, 
using the D-10 Haemoglobin Analyzer (Bio-Rad, USA). 
The FBG was estimated using the glucose oxidase 
method. It should be noted that data on dipeptidyl pepti-
dase-4 (DPP-4) inhibitors and glucagon-like peptide 1 
(GLP-1) receptor agonists were not available in the data-
base. These drugs are not covered by the existing health 
insurance system in China and thus, these drugs are not 
sold in this hospital.18
ethics
The study was ethically approved by the Research Ethics 
Committee at the Ningbo First Hospital, China.
statistical analyses
The 5-year period prevalence of poor glycaemic control 
in patients with T2DM at the diabetes centre was calcu-
lated. Simple logistic regression methods were used to 
investigate the association between glycaemic control and 
other variables. To identify any independent association, 
multiple logistic regression models were developed using 
backward stepwise regression analyses and all the other 
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variables were included. Sensitivity analyses were carried 
out—only those variables with a p value of ≤0.20 in simple 
logistic regressions were included in multiple logistic 
regression models. Multiple regression models included 
a sample with unknown values for these adjusted vari-
ables. ORs and their respective 95% CIs were calculated. 
The results were considered significant when p values 
were ≤0.05. All data were analysed using IBM SPSS Statis-
tics V.20.0 for Windows.
results
Fifty-seven per cent of patients with T2DM were male 
and the mean age was 54.1 years. In terms of HbA1c and 
FBG, the 5-year period prevalence of poor glycaemic 
control was 50.3% (n=698) and 57.3% (n=791), respec-
tively. Table 1 reports the characteristics of patients with 
T2DM with good and poor glycaemic control. In terms of 
HbA1c and FBG, glycaemic control was found to be asso-
ciated with age, education, residence, duration of T2DM 
and T2DM therapeutic regimen. The additional associ-
ated factors were hypertension in the case of HbA1c and 
alcohol drinking and hyperlipidaemia in the case of FBG.
Table 2 shows the multiple backward stepwise logistic 
regression analyses to determine factors independently 
associated with the poor glycaemic control. In terms of 
both HbA1c and FBG, the odds of poor glycaemic control 
increased with the duration of T2DM and were higher 
in patients residing in rural areas, with hyperlipidaemia, 
on diet, physical activity and OHD as part of their T2DM 
therapeutic regimen, and on diet, physical activity, OHD 
and insulin. In addition, in terms of FBG, the odds 
of poor glycaemic control were lower in patients with 
hypertension.
Table 3 reports the sensitivity analyses—multiple logistic 
regression models included only those variables with a 
p value of ≤0.20 in simple logistic regressions. Similar 
results were found in the sensitivity analyses except for 
the association between glycaemic control (in terms of 
FBG) and hypertension.
DIsCussIOn
In terms of HbA1c and FBG, the 5-year period preva-
lence of poor glycaemic control in patients with T2DM 
at the tertiary care diabetes centre in Ningbo, China 
was 50.3% and 57.3%, respectively. In other words, less 
than half of patients with T2DM at the diabetes centre 
have adequate glycaemic control. The finding is consis-
tent with a recent nationwide population-based study 
(51%) and a recent nationwide hospital-based study 
(52%).5 6 However, two other recent nationwide hospi-
tal-based studies reported much higher figures (65% and 
68%).7 8 These hospital-based studies included a range of 
hospitals with different tier levels. In terms of glycaemic 
control in patients with T2DM, tertiary care hospitals 
usually perform better as compared with primary or 
secondary care hospitals,19 and this could be the case in 
our study. Another reason could be different population 
characteristics in these studies. For example, the study 
which reported 68% included only those patients with 
T2DM who were on OHDs alone or in combination with 
either insulin or GLP-1 receptor agonists, indicating poor 
glycaemic control with the disease progression. In spite 
of the availability of diabetes experts at this tertiary care 
diabetes centre, the prevalence of poor glycaemic control 
in patients with T2DM was high in our study as compared 
with other studies conducted in various developed coun-
tries.10 11 Some of the reasons could be non-usage of new 
hypoglycaemic drugs (such as DPP-4 inhibitors and GLP-1 
receptor agonists) and inadequate self-management of 
T2DM in this population. This indicates that there is still 
a room for improvement at this diabetes centre. It should 
be noted that Chinese people are more susceptible to 
T2DM as compared with Whites (eg, they develop T2DM 
at a much younger age).20 It should also be noted that 
blood glucose levels of some patients could be relaxed, 
especially those who are old and frail. However, for the 
purpose of analysis, the glycaemic control was categorised 
into poor and good, based on the current guideline for 
the prevention and management of T2DM in China.16
In the unadjusted models (HbA1c and FBG), glycaemic 
control was found to be associated with age, education, 
residence, duration of T2DM and T2DM therapeutic 
regimen. The additional associated factors were hyper-
tension in the case of HbA1c and alcohol drinking and 
hyperlipidaemia in the case of FBG. Previous studies 
conducted among patients with T2DM in various coun-
tries reported similar and other factors associated with 
glycaemic control (such as age, sex, education, alcohol 
drinking, duration of T2DM, T2DM therapeutic regimen, 
overweight or obese, hypertension and hyperlipi-
daemia).7 19 21–26
The association found between poor glycaemic control 
and longer duration of T2DM is consistent with previous 
studies.8 21 26–28 Since T2DM is a progressive disease, the 
function and mass of β-cells gradually decline with the 
disease progression.29 To attain glycaemic control, a step-
wise approach has been recommended in the national 
T2DM management guideline.16 The first and foremost 
step should be lifestyle modification (ie, diet and phys-
ical activity), followed by addition of OHD(s) and/or 
insulin(s) with the disease progression. An association 
was found between poor glycaemic control and addition 
of OHD(s) and insulin(s), and the finding is consistent 
with previous studies.26 30 This relationship more likely 
represents a marker of T2DM chronicity and severity 
than of medication effects themselves. Another reason 
could be the failure of clinicians to intensify therapy in 
a timely manner.31 32 The uptake and adherence to the 
T2DM therapeutic regimen among patients could also 
be different from what was prescribed.25 32 A recent study 
showed that only 43% of patients with T2DM adhered to 
their therapeutic regimen (OHD(s) and/or insulin(s)) in 
China.33 In the database, data were available on prescrip-
tion but not on uptake and adherence. Thus, these issues 
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  18–39 years 158 (22.9) 81 (11.6) <0.001 135 (22.7) 104 (13.1) <0.001
  40–59 years 323 (46.9) 300 (43.0) 247 (41.4) 376 (47.5)
  ≥60 years 208 (30.2) 317 (45.4) 214 (35.9) 311 (39.3)
Sex 0.157 0.830
  Male 405 (58.8) 384 (55.0) 341 (57.2) 448 (56.6)
  Female 284 (41.2) 314 (45.0) 255 (42.8) 343 (43.4)
Education <0.001 <0.001
  University/college 166 (24.1) 102 (14.6) 145 (24.3) 123 (15.5)
  Class 7–12 333 (48.3) 310 (44.4) 268 (45.0) 375 (47.4)
  Class 1–6 122 (17.7) 204 (29.2) 117 (19.6) 209 (26.4)
  No qualifications 35 (5.1) 67 (9.6) 45 (7.6) 57 (7.2)
  Unknown 33 (4.8) 15 (2.1) 21 (3.5) 27 (3.4)
Occupation 0.064 0.231
  Manual workers 94 (13.6) 121 (17.3) 87 (14.6) 128 (16.2)
  Non-manual workers 138 (20.0) 141 (20.2) 127 (21.3) 152 (19.2)
  Never worked/retired 219 (31.8) 317 (45.4) 211 (35.4) 325 (41.1)
  Unknown 238 (34.5) 119 (17.0) 171 (28.7) 186 (23.5)
Marital status 0.200 0.312
  Married 510 (74.0) 562 (80.5) 446 (74.8) 626 (79.1)
  Single/divorced/widowed 55 (8.0) 77 (11.0) 61 (10.2) 71 (9.0)
  Unknown 124 (18.0) 59 (8.5) 89 (14.9) 94 (11.9)
Residence 0.012 0.042
  Urban 449 (65.2) 412 (59.0) 388 (65.1) 473 (59.8)
  Rural 231 (33.5) 281 (40.3) 202 (33.9) 310 (39.2)
  Unknown 9 (1.3) 5 (0.7) 6 (1.0) 8 (1.0)
Health insurance 0.583 0.704
  Yes 641 (93.0) 644 (92.3) 554 (93.0) 731 (92.4)
  No 48 (7.0) 54 (7.7) 42 (7.0) 60 (7.6)
Smoking 0.076 0.505
  No 567 (82.3) 548 (78.5) 484 (81.2) 631 (79.8)
  Yes 122 (17.7) 150 (21.5) 112 (18.8) 160 (20.2)
Alcohol drinking 0.182 0.040
  No 617 (89.6) 609 (87.2) 539 (90.4) 687 (86.9)
  Yes 72 (10.4) 89 (12.8) 57 (9.6) 104 (13.1)
Family history of T2DM 0.604 0.095
  No 429 (62.3) 444 (63.6) 390 (65.4) 483 (61.1)
  Yes 260 (37.7) 254 (36.4) 206 (34.6) 308 (38.9)
Duration of T2DM
  ≤1 year 207 (30.1) 93 (13.3) <0.001 173 (29.0) 127 (16.1) <0.001
  >1 to 2 years 77 (11.2) 44 (6.3) 55 (9.2) 66 (8.3)
  >2 to 4 years 72 (10.4) 60 (8.6) 53 (8.9) 79 (10.0)
  >4 years 291 (42.2) 487 (69.8) 275 (46.2) 503 (63.6)
  Unknown 42 (6.1) 14 (2.0) 40 (6.7) 16 (2.0)
Continued
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should be explored and be taken into consideration in 
future studies.
The ‘hukou’ system was used to classify patients with 
T2DM into urban or rural residents. An association was 
found between poor glycaemic control and rural resi-
dents, which indicates health inequalities in T2DM 
management. This finding is consistent with another 
recently conducted study in China.5 In addition to poor 
socioeconomic conditions of rural residents in China, no 
or delayed access to healthcare is a major issue in rural 
areas.34 Even the health insurance system is different in 
rural and urban areas.35–37 There are discrepancies in 
resource allocation between rural and urban areas. All 
these could explain the association found between poor 
glycaemic control and rural residents.
Like T2DM, hyperlipidaemia is a risk factor for cardio-
vascular disease.38 The association found between poor 
glycaemic control and hyperlipidaemia is consistent 
with previous studies.26 39 Glycaemic control mainly 
depends on the degree of residual pancreatic β-cells 
function and insulin sensitivity.40 41 It should be noted 
that in Chinese patients with T2DM, the defects in β-cells 
function are more pronounced than decreased insulin 
sensitivity.42 43 Abnormalities in lipid metabolism, charac-
terised by an increase in serum lipids (total cholesterol 
and triglycerides), may result in lipid spill over to non-ad-
ipose tissues, such as pancreatic β-cells. This may lead 
to cellular dysfunction and lipoapoptosis.44 45 It is also 
accepted that high serum triglyceride level is associated 
with insulin resistance.46 These mechanisms may partly 
explain the association found between poor glycaemic 
control and hyperlipidaemia. Further research needs to 
be conducted to confirm the role of hyperlipidaemia in 
long-term glycaemic control. In continuation, early initi-
ation of lipid-lowing therapy in patients with T2DM may 
reduce the risk for cardiovascular disease.
The study has a number of strengths and weaknesses. 
This is the first study to explore glycaemic control in 
patients with T2DM at the tertiary care diabetes centre 
in Ningbo, China. In addition, as far as we are aware, 
this is the first study on this issue in the Zhejiang prov-
ince of China. HbA1c and FBG were used to determine 
glycaemic control, which in turn provided a complete 
















Number of visits to the 
diabetes centre for T2DM 
since registration
8 (4,13)* 8 (5,13)* 0.335 8 (4,13)* 8 (5,13)* 0.214
T2DM therapeutic regimen <0.001 <0.001
  Only diet and physical 
activity
99 (14.4) 45 (6.4) 92 (15.4) 52 (6.6)
  Diet and physical 
activity+OHD
335 (48.6) 296 (42.4) 267 (44.8) 364 (46.0)
  Diet and physical 
activity+insulin
38 (5.5) 27 (3.9) 31 (5.2) 34 (4.3)
  Diet and physical 
activity+OHD+insulin
217 (31.5) 330 (47.3) 206 (34.6) 341 (43.1)
BMI 0.817 0.907
  Under 22 (3.2) 23 (3.3) 21 (3.5) 24 (3.0)
  Normal 289 (41.9) 280 (40.1) 239 (40.1) 330 (41.7)
  Overweight 244 (35.4) 265 (38.0) 222 (37.3) 287 (36.3)
  Obese 101 (14.7) 107 (15.3) 89 (14.9) 119 (15.1)
  Unknown 33 (4.8) 23 (3.3) 25 (4.2) 31 (3.9)
Hypertension 0.005 0.847
  No 321 (46.6) 273 (39.1) 257 (43.1) 337 (42.6)
  Yes 368 (53.4) 425 (60.9) 339 (56.9) 454 (57.4)
Hyperlipidaemia 0.051 0.025
  No 164 (23.8) 136 (19.5) 146 (24.5) 154 (19.5)
  Yes 525 (76.2) 562 (80.5) 450 (75.5) 637 (80.5)
n(%), p value excludes unknown.
*Median (IQR).
BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; OHD, oral hypoglycaemic drug; T2DM, type 2 diabetes 
mellitus.
Table 1 Continued 
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over the past 3 months. On the other hand, FBG is a short-
term index. In terms of generalisability, the study find-
ings could be valid in settings with similar populations 
and healthcare systems. Missing data could lead to bias 
but were generally low in this study. Multiple regression 
analyses included a sample with missing values for the 
adjusted variables. This retrospective study was conducted 
using an existing database, which is primarily developed 
for the clinical purpose and not for research. It is possible 
that our findings were the result of other factors not 
Table 2 Logistic regression analyses to determine factors 
independently associated with poor glycaemic control
OR (95% CI) P value
HbA1c≥7%
  Residence <0.001
   Urban 1
   Rural 1.68 (1.24 to 2.28)
  Duration of T2DM <0.001
   ≤1 year 1
   >1 to 2 years 1.84 (1.06 to 3.19)
   >2 to 4 years 3.32 (1.88 to 5.85)
   >4 years 5.98 (4.09 to 8.75)
  Marital status 0.098
   Married 1
   Single/divorced/widowed 1.45 (0.93 to 2.25)
  T2DM therapeutic regimen 0.001
   Only diet and physical activity 1
   Diet and physical activity+OHD 1.80 (1.01 to 3.23)
   Diet and physical activity+insulin 1.00 (0.43 to 2.33)
   Diet and physical 
activity+OHD+insulin
2.47 (1.38 to 4.41)
  Hyperlipidaemia 0.008
   No 1
   Yes 1.57 (1.12 to 2.19)
FBG>7 mmol/L
  Residence 0.019
   Urban 1
   Rural 1.42 (1.06 to 1.91)
  Duration of T2DM <0.001
   ≤1 year 1
   >1 to 2 years 2.10 (1.22 to 3.62)
   >2 to 4 years 2.48 (1.42 to 4.34)
   >4 years 3.34 (2.32 to 4.80)
  T2DM therapeutic regimen 0.005
   Only diet and physical activity 1
   Diet and physical activity+OHD 2.40 (1.36 to 4.26)
   Diet and physical activity+insulin 2.02 (0.88 to 4.62)
   Diet and physical 
activity+OHD+insulin
2.78 (1.58 to 4.92)
  Hyperlipidaemia 0.002
   No 1
   Yes 1.68 (1.21 to 2.33)
  Hypertension 0.045
   No 1
   Yes 0.73 (0.54 to 0.99)
FBG, fasting blood glucose; HbA1c, glycated haemoglobin; OHD, 
oral hypoglycaemic drug;  T2DM, type 2 diabetes mellitus. 
Table 3 Sensitivity analyses: multiple logistic regression 
models included those variables with p≤0.20 in simple 
logistic regressions
OR (95% CI) P value
HbA1c≥7%
  Residence <0.001
   Urban 1
   Rural 1.68 (1.24 to 2.29)
  Duration of T2DM <0.001
   ≤1 year 1
   >1 to 2 years 1.83 (1.05 to 3.18)
   >2 to 4 years 3.29 (1.88 to 5.77)
   >4 years 5.99 (4.09 to 8.76)
  Marital status 0.096
   Married 1
   Single/divorced/widowed 1.45 (0.94 to 2.25)
  T2DM therapeutic regimen <0.001
   Only diet and physical activity 1
   Diet and physical activity+OHD 1.93 (1.08 to 3.45)
   Diet and physical 
activity+insulin
1.03 (0.45 to 2.39)
   Diet and physical 
activity+OHD+insulin
2.65 (1.49 to 4.72)
  Hyperlipidaemia 0.007
   No 1
   Yes 1.58 (1.13 to 2.20)
FBG>7 mmol/L
  Residence 0.044
   Urban 1
   Rural 1.28 (1.01 to 1.62)
  Duration of T2DM <0.001
   ≤1 year 1
   >1 to 2 years 1.67 (1.08 to 2.60)
   >2 to 4 years 2.16 (1.40 to 3.33)
   >4 years 2.51 (1.89 to 3.32)
  T2DM therapeutic regimen 0.002
   Only diet and physical activity 1
   Diet and physical activity+OHD 1.90 (1.25 to 2.89)
   Diet and physical 
activity+insulin
1.66 (0.87 to 3.19)
   Diet and physical 
activity+OHD+insulin
2.30 (1.50 to 3.52)
  Hyperlipidaemia 0.020
   No 1
   Yes 1.39 (1.05 to 1.83)
FBG, fasting blood glucose; HbA1c, glycated haemoglobin; OHD, 
oral hypoglycaemic drug; T2DM, type 2 diabetes mellitus.
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present in the database and thus, not adjusted for in the 
models, such as self-monitoring of blood glucose, uptake 
and adherence to the T2DM therapeutic regimen and 
depression, anxiety and stress levels of patients.25 47 48 
Although the data were available on time, however, the 
other data quality issues of routinely collected data cannot 
be ignored, such as accuracy and reliability. Some of the 
data were self-reported (eg, duration of T2DM), and 
recall error could have been a problem. This inaccurate 
measurement of the variable could mean that individuals 
were assigned to the wrong category and then resulted 
in an incorrect estimation of the association between 
duration of T2DM and poor glycaemic control. As this 
was a cross-sectional study, it was not possible to deter-
mine the causal association between different variables 
and glycaemic control. A long-term, longitudinal study 
should be conducted among these patients to assess the 
impact of various factors (these as well as other poten-
tial factors) on their glycaemic control. Ours was a hospi-
tal-based study and a population-based study should be 
conducted, which might give a different picture. This 
could be because of different population characteristics, 
including their healthcare-seeking behaviour.
In conclusion, more than half of patients with T2DM at 
the diabetes centre in Ningbo, China have poor glycaemic 
control, and the predictors of glycaemic control were 
identified. The study findings could be taken into 
consideration in future interventional studies aimed at 
improving glycaemic control in these patients.
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